 X. To validate the neurotoxicity items in the Symptoms in Relation to Patient Functioning Survey C-1271 used in this protocol by correlating its results with the Functional Assessment of Cancer Therapy FACT-Neurotoxicity Subscale C-669 and the European Organization for Research and Treatment of Cancer EORTC Quality of Life Questionnaire QLQ-Core C30 and Breast Cancer module C-259 and C-618. 